| abstract |
bruton tyrosine kinase inhibitors are disclosed herein reversible and irreversible bruton tyrosine kinase (btk) inhibitors. pharmaceutical compositions that include the compounds are also disclosed. methods of using btk inhibitors are described, separately or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. |